Acadia Pharmaceuticals B.V.
1 products tracked · names used in filings: Acadia Pharmaceuticals B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Thu 20 Aug 2026🇪🇺 EU approval (EC decision)
Daybu (trofinetide) approved in the EU
Marketing authorisation to Acadia Pharmaceuticals B.V.; Orphan, Additional monitoring · source
Thu 25 Jun 2026🇪🇺 CHMP positive opinion
Daybu (trofinetide): CHMP positive opinion
Acadia Pharmaceuticals B.V.; Orphan, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Daybu trofinetide | Authorised | 2026-08-20 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.